Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Update on hematology work in Oxford

Karthik Ramasamy • 13 Jun 2019
EHA 2019
General

Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives us an update on hematology work in Oxford. This interview took place in the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Karthik Ramasamy

Baseline findings from the SECURE study of incidentally detected MGUS in the UK
2:01
Baseline findings from the SECURE study of incidentally detected MGUS in the UK
Karthik Ramasamy • 23 Sep 2026
Managing ultra-high-risk and double-hit multiple myeloma
1:19
Managing ultra-high-risk and double-hit multiple myeloma
Karthik Ramasamy • 23 Sep 2026
Exploring the association between PFS and OS in patients with R/R MM from a real-world perspective
1:18
Exploring the association between PFS and OS in patients with R/R MM from a real-world perspective
Karthik Ramasamy • 23 Sep 2026
Findings from a MAIC of BVd versus KRd in second-line myeloma treatment
1:23
Findings from a MAIC of BVd versus KRd in second-line myeloma treatment
Karthik Ramasamy • 23 Sep 2026

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals